ALNY - Alnylam submits application to begin trial of type 2 diabetes treatment in Canada

• Alnylam Pharma ( NASDAQ: ALNY ) said on Wednesday it had submitted an application to begin trial of ALN-KHK, an investigational RNAi therapy targeting ketohexokinase to treat Type 2 diabetes mellitus (T2DM) to Health Canada.
• The company plans to begin enrollment in a Phase 1/2 study in overweight to obese volunteers and obese patients with T2DM in early 2023, and expects to report initial data in late 2023.
• Obesity is a risk factor for both T2DM and fatty liver disease. Fructose predisposes to fatty liver disease and thus, in the context of T2DM, aggravates insulin resistance.
• The company believes targeting ketohexokinase, also known as fructokinase, is a new therapeutic approach to reduce fatty acid synthesis and insulin resistance.

For further details see: